Lutetium-177 PSMA radioligand therapy in taxan-naive first- and second-line metastatic castration resistant prostate cancer after first-line ARPI therapy.

Eur J Nucl Med Mol Imaging · 2025 · PMC12014794 · PMID 39804375

Europe PMC DOI

hedged sentence

0.2000

closest p · 4.0× alpha

0.2000

boldest claim

The sentences

failed to reach statistical significancep = 0.2not close (p > 0.1)

In univariable OS analyses, the benefit of Lu-PSMA failed to reach statistical significance (HR: 0.64, p = 0.2), however, a clinically meaningful median OS difference of 68.9 (CI: 41-NR]) vs. 39.1 (CI: 32.8–63.0) months in favor of Lu-PSMA treatment was observed.

also in 6,035 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.